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Unidad de Trasplante de Progenitores Hematopoyéticos, Buenos Aires, Argentina; 4Hospital das Clinicas da Faculda de Medicina de Ribeirão Preto, Ribeirão Preto, Brazil;
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Background
Aplastic anemia (AA) is a rare but serious disease that affects hematopoietic stem cells and is
characterized by pancytopenia and a hypocellular bone marrow. It can be a hereditary or acquired
condition. Acquired AA has an incidence of 2 per million per year in Europe, but the incidence is two to
three times higher in Asia. In Latin America, there is little epidemiologic data on this disease. The most
important treatments for AA are bone marrow transplantation and immunosuppressive treatment with
antithymocyte globulin and cyclosporine. But access to these treatments is restricted in some areas of
Latin America.
At the American Society of Hematology (ASH) Annual Meeting in 2016, representatives of the
Hematology Societies of Latin America, with the support of the ASH International Program, met to
discuss possible collaborative efforts. Everyone agreed that lack of reliable information is one of the main
barriers to designing significant clinical trials for the region; therefore, starting a registry of hematologic
diseases for the region has become a main goal of the group. In April 2017, at the ASH Highlights
meeting in Latin America, AA was selected as the first disease that would be used to begin the
collaborative action. National hematology societies of Argentina, Bolivia, Brazil, Chile, Colombia, Costa
Rica, Paraguay, Peru, Uruguay, and Venezuela have made a commitment to help develop the Latin
American Registry for Aplastic Anemia (LARAA) (Table 1). Figure 1 shows countries and the number of
centers in each country that are likely to collaborate on building the registry.
Objectives
c Develop a multinational Latin American research group interested in studying AA in the region, its
clinical characteristics, and therapeutic approaches;
c Develop a Latin American Registry of patients with acquired AA to determine the current status of the
disease in the region; and
c Work together to improve diagnosis and treatment of AA by encouraging local action.
LARAA timeline
2016
c December: ASH Annual Meeting in San Diego, CA. We agreed to design a collaborative effort
across countries, to refine data collection efforts, and to start a collaborative registry project.
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